Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5528680 | 0.98 | IDO1 (0.67) | IDO1CYP19A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL402251 | 0.81 | IDO1 (0.62) | IDO1CYP3A4TSHRLMNAALDH1A1 | |
| SCHEMBL11273785 | 0.81 | CYP19A1 (0.50) | IDO1CYP19A1CYP3A4SMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL5529280 | 0.80 | IDO1 (0.64) | IDO1CYP3A4TSHRLMNAALDH1A1 | |
| SCHEMBL9808020 | 0.79 | CYP19A1 (0.48) | IDO1CYP19A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL439093 | 0.79 | IDO1 (1.00) | IDO1POLBTSHRLOXL2ALDH1A1 | |
| Dinitrophenylene SCHEMBL28061358 | 0.78 | IDO1 (0.64) | IDO1SMN1; SMN2TSHRLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL659130 | 0.78 | IDO1 (1.00) | IDO1CYP3A4TSHRLOXL2 | |
| SCHEMBL7005132 | 0.76 | CYP19A1 (0.45) | IDO1CYP19A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL7005138 | 0.76 | CYP19A1 (0.45) | IDO1CYP19A1CYP3A4SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| EP-3097925-B1 | PHARMACEUTICAL COMPOSITION | AC IMMUNE SA (CH) | 2019-06-12 | — | — | EP | disclosed |
| EP-3097925-A1 | PHARMACEUTICAL COMPOSITION | AC Immune S.A. (CH) | 2016-11-30 | — | — | EP | disclosed |
| EP-2413957-B1 | PHARMACEUTICAL COMPOSITION | AC IMMUNE SA (CH) | 2016-07-27 | — | — | EP | disclosed |
| CN-102946899-B | Pharmaceutical composition | AC IMMUNE S.A. (CH) | 2016-01-20 | — | — | CN | disclosed |
| US-20150259406-A1 | Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines | AC IMMUNE SA (CH) | 2015-09-17 | — | — | US | disclosed |
| US-20140255412-A1 | Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines | UNIV LEUVEN KATH (BE) | 2014-09-11 | — | — | US | disclosed |
| US-8647631-B2 | Pharmaceutical composition of an antigenic tau peptide reconstituted in a liposome and related antibodies and cell lines | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-02-11 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120183599-A1 | Pharmaceutical Composition | AC IMMUNE S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| EP-2413957-A2 | PHARMACEUTICAL COMPOSITION | AC Immune S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2010115843-A2 | PHARMACEUTICAL COMPOSITION | AC IMMUNE S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP19A1 580/4885CYP3A4 413/4885 |
| US-20150259406-A1 | Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines | PSEN1, MAPT, PHOSPHO1 | IDO1 4246/4885CYP19A1 4572/4885CYP3A4 4859/4885 |
| US-20140255412-A1 | Pharmaceutical Composition of an Antigenic Tau Peptide Reconstituted in a Liposome and Related Antibodies and Cell Lines | PSEN1, MAPT, PHOSPHO1 | IDO1 4246/4885CYP19A1 4572/4885CYP3A4 4859/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP19A1 549/4885CYP3A4 499/4885 |
| US-20120183599-A1 | Pharmaceutical Composition | MAPT, PSEN1, PSEN2 | IDO1 3047/4885CYP19A1 4103/4885CYP3A4 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.